Oculis Operations Sarl

Key Pharmaceuticals, Inc.

Lipid Pharmaceuticals Ehf.

Oculis Ehf

Oculis Sa

University of Florida Research Foundation Inc

Decode Genetics Ehf

Cyclops, Ehf.

Cyclops H.f.

Thorsteinn Loftsson

Zoltán Fülöp

Einar Stefansson

Nicholas S Bodor

Zoltan Fulop

Mar Masson

Einar Stefánsson

Zoltán Fulop

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

PH stabilized ophthalmic compositions

Treatment of ocular inflammation following ocular surgery

PH stabilized ophthalmic dexamethasone compositions

Stabilized ophthalmic dexamethasone compositions

Treatment of ocular inflammation with ophthalmic compositions

Treatment of diabetic retinopathy with ophthalmic compositions

The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.

Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery

A method is described of stabilizing the pH of an aqueous composition including a drug that is prone to oxidation. The method includes adding an additive to prevent oxidation of the drug that is prone to oxidation. Also described, is a method of stabilizing the pH of an aqueous composition including a corticosteroid, the method including adding an additive to prevent oxidation of the corticosteroid. Further, a composition is described that includes a corticosteroid and an additive to prevent oxidation of the corticosteroid.

Diabetic retinopathy treatment with stabilized dexamethasone

Stabilized dexamethasone compositions

Treatment of diabetic retinopathy

Treatment of ocular inflammation

An anti-viral composition or formulation is described that includes free fatty acids ('FFA'). Also described, are methods of making and using such a composition or formulation.

Free fatty acids and methods of manufacture and use for treating coronavirus and other viral respiratory infections

The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 &#x3bc;m.

The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g.), viral infections (e.g. herpes simplex virus infections) and inflammations, as well as against fissura ani and pruritus ani.

Fatty acids for use as a medicament

Growing community of inventors

Reykjavik, Iceland

Thorsteinn Loftsson